Evelien Nollet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Evelien Nollet has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Christiaan J. Vrints
Laboratory of Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Antwerp, Belgium; Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
3 shared publicationsDina De Bock
Department of Cardiac Surgery, Antwerp University Hospital, Antwerp, Belgium
3 shared publicationsEmeline M. Van Craenenbroeck
Laboratory of Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Antwerp, Belgium; Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
3 shared publications- Viviane Van Hoof
Department of Clinical Chemistry, Antwerp University Hospital, Edegem, Belgium; Translational Pathophysiological Research Group, University of Antwerp, Edegem, Belgium
3 shared publications Marc Dom
Department of Stomatology and Maxillofacial Surgery, Antwerp University Hospital, Antwerp, Belgium; Department of Oral and Maxillofacial Surgery, General Hospital Sint-Maarten, Duffel, Belgium
2 shared publicationsVicky Y. Hoymans
Laboratory of Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Antwerp, Belgium
2 shared publications
Latest Publications
- 1 May 2017
- Published by Elsevier in Atherosclerosis
- Vol. 260, 138-146
Accelerated cellular senescence as underlying mechanism for functionally impaired bone marrow-derived progenitor cells in ischemic heart disease
- 1 May 2017
- Published by Elsevier in Atherosclerosis
- Vol. 260, 138-146
Accelerated cellular senescence as underlying mechanism for functionally impaired bone marrow-derived progenitor cells in ischemic heart disease
- Open Access
- 25 July 2016
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 9 (4) , 266-278
Bone Marrow-Derived Progenitor Cells Are Functionally Impaired in Ischemic Heart Disease
To determine whether the presence of ischemic heart disease (IHD) per se, or rather the co-presence of heart failure (HF), is the primum movens for less effective stem cell products in autologous stem cell therapy, we assessed numbers and function of bone marrow (BM)-derived progenitor cells in patients with coronary artery disease (n = 17), HF due to ischemic cardiomyopathy (n = 8), non-ischemic HF (n = 7), and control subjects (n = 11). Myeloid and erythroid differentiation capacity of BM-derived mononuclear cells was impaired in patients with underlying IHD but not with non-ischemic HF. Migration capacity decreased with increasing IHD severity. Hence, IHD, with or without associated cardiomyopathy, is an important determinant of progenitor cell function. No depletion of hematopoietic and endothelial progenitor cells (EPC) within the BM was observed, while circulating EPC numbers were increased in the presence of IHD, suggesting active recruitment. The observed myelosuppression was not driven by inflammation and thus other mechanisms are at play.
- 25 July 2016
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 9 (4) , 266-278
Open AccessBone Marrow-Derived Progenitor Cells Are Functionally Impaired in Ischemic Heart Disease
To determine whether the presence of ischemic heart disease (IHD) per se, or rather the co-presence of heart failure (HF), is the primum movens for less effective stem cell products in autologous stem cell therapy, we assessed numbers and function of bone marrow (BM)-derived progenitor cells in patients with coronary artery disease (n = 17), HF due to ischemic cardiomyopathy (n = 8), non-ischemic HF (n = 7), and control subjects (n = 11). Myeloid and erythroid differentiation capacity of BM-derived mononuclear cells was impaired in patients with underlying IHD but not with non-ischemic HF. Migration capacity decreased with increasing IHD severity. Hence, IHD, with or without associated cardiomyopathy, is an important determinant of progenitor cell function. No depletion of hematopoietic and endothelial progenitor cells (EPC) within the BM was observed, while circulating EPC numbers were increased in the presence of IHD, suggesting active recruitment. The observed myelosuppression was not driven by inflammation and thus other mechanisms are at play.
- Open Access
- 1 June 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 446, 253-260
Bone matrix vesicle-bound alkaline phosphatase for the assessment of peripheral blood admixture to human bone marrow aspirates
- 1 June 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 446, 253-260
Open AccessBone matrix vesicle-bound alkaline phosphatase for the assessment of peripheral blood admixture to human bone marrow aspirates